BiondVax Pharmaceuticals, a publicly-traded company in Israel (TASE: BVXV) and the United States (NASDAQ: BVXV), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax’s Universal Flu Vaccine is based on research carried out over two decades by Weizmann Institute of Science Professor Ruth Arnon, who heads the company’s Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment of multiple sclerosis.

BiondVax 8-pager on Slideshare

BiondVax’s technology utilizes a unique, proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, for developing, manufacturing and commercializing this innovative flu vaccine.

BiondVax has a unique market strategy for its lead candidate M-001. It first looks to obtain regulatory approval for M-001 as a primer to a pandemic or seasonal vaccine, and after accumulating enough safety and efficacy from real world data, the product will be tested and approved as a universal standalone vaccine for any existing or future pandemic or seasonal flu.

M-001 has successfully completed 5 human clinical trials, with two ongoing Phase 2 trials.

BiondVax’s team of 15 includes scientists, technicians, researchers, and administrative staff. The company’s state-of-the-art GMP facility in Ness-Ziona, Israel, houses its laboratories, production facilities and offices.

Please follow the link to see a video of BiondVax’s production facilities and lab.

To date, BiondVax has raised a total of over US$29 million. In 2015, BiondVax started trading on the NASDAQ, raising $9.5 million in American Depository Shares.

Read BiondVax’s Code of Conduct and Business Ethics